Moderna stock jumps 5% after FDA approved second booster for ages 50 up

Though the FDA approval on Tuesday applies to the mRNA vaccines from both Modena and Pfizer, much-larger Pfizer is not dependent on the vaccine for profits and saw its shares drop.